earnings
confidence high
sentiment positive
materiality 0.85
GeneDx prelim FY2025 rev $427M (+41%); FY2026 guidance $540-555M
GeneDx Holdings Corp.
2025-FY EPS reported
-$0.73
revenue$427,539,000
- FY2025 exome/genome revenue ~$360M (+54% YoY); Q4 $104M (+32% YoY).
- Exome/genome volume 97,271 (+30.5%) for FY2025; Q4 volume up 34.3%.
- Adjusted gross margin 71% in Q4 and FY2025; cash & equivalents $172M.
- FY2026 guidance: rev $540-555M, 33-35% exome/genome growth, adj gross margin ≥70%.
- Expects positive adjusted net income in FY2026.